Press release
The University of Dundee is leading an international collaboration with the intention of developing the first vaccine for Strep A.
Press release
The University of Dundee is leading an international collaboration with the intention of developing the first vaccine for Strep A.
Press release
World-leading expertise from the University of Dundee’s Centre for Targeted Protein Degradation (CeTPD) will contribute to a new, global effort to tackle some of the most significant challenges posed by cancer.
Press release
A breakthrough class of molecular glue identified at the University of Dundee could pave the way for a new generation of drugs to target cancers and neurodegenerative diseases.
Press release
University of Dundee researchers have developed a new molecule that is able to target and bind to a protein class previously considered undruggable by using a masking technique to enter the cell
News
Dr Will Farnaby, Principal Investigator in the Centre for Targeted Protein Degradation (CeTPD), has been awarded a Wellcome Trust Early Career Award.
Press release
A new University of Dundee spinout opportunity hopes to create vaccines against Strep A as well as novel vaccines for other human and animal diseases, while reducing our reliance on antibiotics.
Press release
A successful collaboration between the University of Dundee and pharmaceutical company Eisai Co Ltd aiming to create innovative new cancer drugs has been extended for a further three years.
Press release
An international collaboration, featuring scientists from the University of Dundee, has made a breakthrough they hope will help futureproof a revolutionary new field of drug discovery by preventing resistance in cancer therapy.
Press release
Scientists have designed a novel molecule capable of destroying an as-yet undruggable cancer-causing protein – and are making it available for researchers around the world to use in their own work, free of charge
Press release
Researchers from the University of Dundee have discovered a small molecule that helps to eliminate a Parkinson’s disease-causing protein
News
Amphista Therapeutics, the spin out company from the lab of Professor Alessio Ciulli, was awarded the ‘Financing Deal of the Year’ award 2021 at the Scrip Awards last month. This was in recognition of their $53M Series B funding.
Press release
Researchers from the University of Dundee and Promega Corporation have shown how a “three-headed hydra” significantly improves efficacy in a field of chemical biology that is revolutionising drug discovery.
Press release
Scientists at the University of Dundee have developed a new technology that provides a greater understanding into the biology of ‘undruggable’ diseases.
Press release
The expansion of an exemplary industry-academia collaboration will see the University of Dundee intensify its efforts to develop new medicines that target and destroy key cancer-causing proteins, which have previously been regarded as undruggable
Press release
A new translational research centre will bolster the University of Dundee’s world-leading position in a field that is revolutionising drug discovery, while helping to facilitate the development of high growth companies and create skilled jobs.
Press release
Amphista Therapeutics, a University of Dundee spinout company, has announced a near-£40 million investment that will further its work to develop new drugs for a range of diseases.
News
Two life sciences researchers have been awarded Future Leaders Fellowships from UK Research and Innovation (UKRI).
Press release
The University of Dundee is to partner with global biopharmaceutical company Almirall to develop new treatments for severe skin diseases with high level of unmet medical need.
News
Natalie Bamford, a Postdoctoral Research Assistant in the lab of Nicola Stanley-Wall, has been awarded a prestigious two-year EMBO Long-term fellowship.
News
Megan Bergkessel and Leeanne McGurk have been awarded funding from the Springboard scheme of the Academy of Medical Sciences, which is designed to help early career researchers establish their independent research programmes.